A Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Comparing Two Titration Regimens

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Comparing Two Titration Regimens

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Acronyms TITRATION
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 22 Nov 2017 Results of post-hoc analysis assessing relationship between SBP and initiation and up-titration of sacubitril/valsartan published in the European Journal of Heart Failure
    • 10 Jun 2017 Biomarkers information updated
    • 12 May 2016 Results published in the European Journal of Heart Failure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top